DailyIQ
DailyIQ
NTRANatera, Inc.

Earnings Release

Natera, Inc.'s latest earnings press release, filed Nov 5, 2026, scored line by line for tone, guidance and what changed since the prior release.

No guidance given56 lines scoredFiled Nov 5, 2026SEC 8-K · Exhibit 99
Release Tone
67
UPBEAT
GuidanceNo guidance givenWhat this release does to the company's outlook
Tone change▼ 10.2pointsvs the prior release (Aug 6, 2026)
Hedging language3.32per 100 words▲ 0.61 vs prior
New this quarter23of 56 linesWording that was not in the prior release

The lines that matter most

Ranked by how material, how strongly worded and how new each sentence is.

  1. 1

    Increased cash by approximately $5.7 million 3 as of September 30, 2026 compared to June 30, 2026.

    New this quarter
  2. 2

    Changes in estimates for the three months ended September 30, 2026 and 2025 increased revenue and, as a result, increased gross margin 1 by 1.5% and 3.6%, respectively, and increased gross profit 1 by $32.3 million and $55.1 million, respectively.

  3. 3

    Excluding revenue true-ups, third quarter non-GAAP gross margin 2 increased by 137 basis points over the second quarter of 2026.

  4. 4

    Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance.

    New this quarter
  5. 5

    Processed approximately 339,500 oncology tests in the third quarter of 2026, compared to approximately 211,000 in the third quarter of 2025, an increase of 60.9%.

  6. 6

    Processed approximately 1,093,100 tests in the third quarter of 2026, compared to approximately 893,600 tests in the third quarter of 2025, an increase of 22.3%.

  7. 7

    Total revenues were $794.0 million in the third quarter of 2026 compared to $592.2 million in the third quarter of 2025, an increase of 34.1%.

  8. 8

    Generated total revenues of $794.0 million in the third quarter of 2026, compared to $592.2 million in the third quarter of 2025, an increase of 34.1%.

Release by release

Tone and guidance for the last 3 earnings releases.

  1. Nov 5, 2026No guidance given66.7-10.2
  2. Aug 6, 2026Guidance raised76.9+1.4
  3. May 7, 2026Guidance raised75.5

Bar length: tone on a 50–82 scale.

The release, annotated

1Highlight rankPositive toneNeutralNegative toneDimmed text: low materiality
Natera Reports Third Quarter 2026 Financial Results
AUSTIN, Texas, November 5, 2026 /BUSINESS WIRE/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026.
Recent Financial Highlights
8Generated total revenues of $794.0 million in the third quarter of 2026, compared to $592.2 million in the third quarter of 2025, an increase of 34.1%.
Generated a gross margin 1 of 64.7% in the third quarter of 2026, compared to a gross margin 1 of 64.9% in the third quarter of 2025.
3Excluding revenue true-ups, third quarter non-GAAP gross margin 2 increased by 137 basis points over the second quarter of 2026.
6Processed approximately 1,093,100 tests in the third quarter of 2026, compared to approximately 893,600 tests in the third quarter of 2025, an increase of 22.3%.
5Processed approximately 339,500 oncology tests in the third quarter of 2026, compared to approximately 211,000 in the third quarter of 2025, an increase of 60.9%.
Clinical molecular residual disease (MRD) oncology units grew 32,700 units over the second quarter of 2026.
1Increased cash by approximately $5.7 million 3 as of September 30, 2026 compared to June 30, 2026.
Raised 2026 annual revenue guidance by $140 million at the midpoint, from $2.850 billion - $2.910 billion to $3.005 billion - $3.035 billion.
Third Quarter Ended September 30, 2026 Financial Results
7Total revenues were $794.0 million in the third quarter of 2026 compared to $592.2 million in the third quarter of 2025, an increase of 34.1%.
The increase in revenues was driven by an increase in volume and average selling price improvements.
Natera processed approximately 1,093,100 tests in the third quarter of 2026, including approximately 1,080,300 tests accessioned in its laboratory, compared to approximately 893,600 tests processed, including approximately 879,700 tests accessioned in its laboratory, in the third quarter of 2025.
In the third quarter of 2026, Natera recognized revenue on approximately 1,024,800 tests for which results were reported to customers in the period (tests reported), including approximately 1,012,100 tests reported from its laboratory, compared to approximately 832,900 tests reported, including approximately 819,900 tests reported from its laboratory, in the third quarter of 2025, an increase of 23.0% from the prior period.
Gross profit 1 for the three months ended September 30, 2026 and 2025 was $513.5 million and $384.4 million, respectively, representing a gross margin 1 of 64.7% and 64.9%, respectively.
This was primarily as a result of higher revenues and continued progress in reducing cost of revenues, offset by a smaller benefit from changes in estimates.
2Changes in estimates for the three months ended September 30, 2026 and 2025 increased revenue and, as a result, increased gross margin 1 by 1.5% and 3.6%, respectively, and increased gross profit 1 by $32.3 million and $55.1 million, respectively.
The decrease in the change in estimate reflects the continued accumulation of historical collection experience, which has resulted in our estimates of variable consideration at the time of revenue recognition more closely approximating subsequent cash collections.
Gross margin 1 for the three months ended June 30, 2026 was 64.5%.
Excluding the change in estimates in revenue accruals of approximately $32.3 million and $52.3 million during the three months ended September 30, 2026 and June 30, 2026, respectively, Natera's non-GAAP gross margin 2 increased by approximately 1.4% sequentially.
Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the third quarter of 2026 was $576.1 million, compared to $482.0 million in the same period of the prior year, an increase of 19.5%.
The increase was primarily driven by headcount growth to support new product offerings as well as increases in clinical trial expenses.
Amortization of acquired intangible assets for the third quarter of 2026 was $5.7 million.
No such amortization occurred in the third quarter of 2025.
Loss from operations for the third quarter of 2026 was $68.3 million compared to $97.6 million for the same period of the prior year.
Natera’s net loss for the third quarter of 2026 was $59.9 million, or ($0.42) per diluted share, compared to a net loss of $87.5 million, or ($0.64) per diluted share, in the third quarter of 2025.
Weighted average shares outstanding were 144.1 million in the third quarter of 2026 compared to 137.2 million for the same period in the prior year.
At September 30, 2026, Natera held approximately $1,097.2 million in cash, cash equivalents, and restricted cash, compared to $1,076.1 million as of December 31, 2025.
As of September 30, 2026, Natera had a total outstanding debt balance of $80.3 million, including accrued interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.
Financial Outlook
Natera anticipates 2026 total revenue of $3.005 billion to $3.035 billion; gross margin 1 to be approximately 64% to 66%; selling, general and administrative costs to be approximately $1.225 billion to $1.300 billion; research and development costs to be $825 million to $925 million; and cash flow to be positive.
Test Volume Summary
UnitQTD 2026QTD 2025Definition
Tests processed1,093,100893,600Tests accessioned in our laboratory plus units processed outside of our laboratory
Tests accessioned1,080,300879,700Tests accessioned in our laboratory
Tests reported1,024,800832,900Total tests reported
Tests reported in our laboratory1,012,100819,900Total tests reported in our laboratory less units reported outside of our laboratory
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health.
We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.
4Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance.
Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, San Carlos, California, and Boulder, Colorado.
For more information, visit www.natera.com.
Date:Thursday, November 5, 2026
Time:1:30 p.m. PT (4:30 p.m. ET)
Conference ID:221 556 643
our laboratory partners; we have incurred net losses since our inception and we anticipate that we will continue to incur net losses for the foreseeable future; our quarterly results may fluctuate from period to period; unless otherwise indicated, all financial data for the current and prior quarters are unaudited and subject to adjustment in connection with the completion of our quarterly and annual financial reporting processes; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; our products may not perform as expected; the results of our clinical studies may not support the use and reimbursement of our tests, particularly for microdeletions screening, and may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified laboratories becomes inoperable, we will be unable to perform our tests and our business may be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for our tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors; we could incur substantial costs and delays complying with governmental regulations; litigation and other regulatory or governmental proceedings related to our intellectual property or the commercialization of our tests, are costly, time-consuming, could result in our obligation to pay material judgments or incur material settlement costs, and could limit our ability to commercialize our tests; and any inability to effectively protect our proprietary technology could harm our competitive position or our brand.
We discuss these and other risks and uncertainties in greater detail in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our periodic reports on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time.
These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC’s website at www.sec.gov.
We operate in a very competitive and rapidly changing environment.
New risks emerge from time to time.
Gross profit is calculated as GAAP total revenues less GAAP cost of revenues.
Gross margin is calculated as gross profit divided by GAAP total revenues.
Excluding the change in estimates in revenue accruals of approximately $32.3 million and $52.3 million during the three months ended September 30, 2026 and June 30, 2026, respectively, Natera’s non-GAAP gross margin increased by approximately 1.4% sequentially.
Includes GAAP cash, cash equivalents and restricted cash.
21 boilerplate lines (safe-harbor disclaimer, contacts, call details) are set aside.

How this is scored

  • Source: the press release Natera, Inc. filed with the SEC as Exhibit 99 to Form 8-K (Item 2.02). Financial statements and boilerplate are set aside.
  • Tone: a financial sentiment model scores each sentence 0 to 100; the release score weights sentences by how material they are.
  • Materiality and guidance: a classifier judges whether each sentence is specific information, and what the release does to the outlook.
  • New this quarter: wording that does not appear in the prior release.
  • Hedging: uncertainty words (may, could, approximately, headwinds and similar) per 100 words of narrative.

These scores describe the release's language. They are not a forecast or a recommendation. Read the original filing

Back to NTRA overview